+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Blood Cancer Drugs Market by Therapeutic Class, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Blood Cancer Drugs Market by Therapeutic Class, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Blood Cancer Drugs Market by Therapeutic Class, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010967
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The blood cancer drugs market is evolving rapidly, shaped by advancements in therapeutics, shifting regulatory frameworks, and dynamic global supply chains. Senior decision-makers face a landscape marked by increased complexity and significant opportunities as scientific innovations converge with regional market growth.

Market Snapshot: Blood Cancer Drugs Market

The Blood Cancer Drugs Market grew from USD 45.98 billion in 2024 to USD 50.96 billion in 2025. It is expected to continue growing at a CAGR of 10.33%, reaching USD 82.96 billion by 2030. This growth reflects ongoing clinical development, expanding access to advanced therapies, and emerging opportunities in precision medicine. A robust pipeline of innovative treatments is redefining the standard of care, while regional initiatives drive market diversification and access.

Scope & Segmentation

  • Therapeutic Class: Chemotherapy, Immunotherapy, Stem Cell Transplant, Targeted Therapy
  • Indication: Leukemia (Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), Multiple Myeloma (First Line, Second Line, Third Line And Later), Myelodysplastic Syndromes
  • Route of Administration: Intravenous, Oral, Subcutaneous
  • Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
  • End User: Clinics, Home Care, Hospitals
  • Regional Coverage: Americas (United States: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Company Coverage: Bristol-Myers Squibb Company, AbbVie Inc., Roche Holding AG, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Amgen Inc., Novartis AG, AstraZeneca plc, Gilead Sciences, Inc., Sanofi S.A.

Key Takeaways

  • Innovative treatments like immunotherapies, targeted agents, and advanced cellular approaches are reshaping blood cancer care by enabling more personalized regimens.
  • Integration of companion diagnostics and digital health tools is improving candidate selection, treatment adherence, and real-time clinical decision support.
  • Regional variations require tailored market entry strategies, with the Americas emphasizing early adoption, EMEA focusing on supply chain maturity, and Asia-Pacific driving fast-growth initiatives and local manufacturing.
  • Collaborative models—such as consortiums, public-private partnerships, and cross-sector alliances—are accelerating the translation of research into clinical advancements while distributing risk across the value chain.
  • Value-based reimbursement models and outcomes-driven frameworks are influencing investment, pricing, and pipeline prioritization, supporting sustainable long-term growth.

Tariff Impact on US Market

The introduction of revised import tariffs on active pharmaceutical ingredients and finished therapies in early 2025 is generating operational challenges for the US blood cancer drugs market. These reforms have increased manufacturing costs and pressured supply chains, leading to price escalations and prompting a strategic shift toward nearshoring and regional production hubs. Market stakeholders are adapting by renegotiating contracts, diversifying suppliers, and reassessing R&D investments to mitigate downstream pricing uncertainties and margin pressures. While these changes create short-term volatility, they are also driving technological innovation and collaboration to achieve greater supply chain resilience.

Methodology & Data Sources

This report synthesizes findings from primary interviews with oncologists, executives, and regulatory experts alongside an extensive secondary review of clinical registries, corporate filings, patent databases, and industry assessments. Quantitative and qualitative insights were validated through cross-referencing and expert panels to deliver robust, unbiased market intelligence.

Why This Report Matters

  • Delivers actionable insights on segmentation, technology adoption, and regional growth to support strategic planning.
  • Equips decision-makers with evidence-based analysis of tariff impacts and evolving reimbursement models for informed risk and investment management.
  • Offers a comprehensive overview of competitive dynamics and partnership opportunities to optimize market positioning and product lifecycle strategies.

Conclusion

The blood cancer drugs market is poised for continued transformation as stakeholders prioritize precision medicine, supply chain adaptability, and digital health integration. This report empowers leaders to navigate change, seize growth opportunities, and shape patient-centric outcomes in a competitive global landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Blood Cancer Drugs Market, by Therapeutic Class
8.1. Introduction
8.2. Chemotherapy
8.3. Immunotherapy
8.4. Stem Cell Transplant
8.5. Targeted Therapy
9. Blood Cancer Drugs Market, by Indication
9.1. Introduction
9.2. Leukemia
9.2.1. Acute Lymphoblastic Leukemia
9.2.2. Acute Myeloid Leukemia
9.2.3. Chronic Lymphocytic Leukemia
9.2.4. Chronic Myeloid Leukemia
9.3. Lymphoma
9.3.1. Hodgkin Lymphoma
9.3.2. Non-Hodgkin Lymphoma
9.4. Multiple Myeloma
9.4.1. First Line
9.4.2. Second Line
9.4.3. Third Line And Later
9.5. Myelodysplastic Syndromes
10. Blood Cancer Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
11. Blood Cancer Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Blood Cancer Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
13. Americas Blood Cancer Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Blood Cancer Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Blood Cancer Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Bristol-Myers Squibb Company
16.3.2. AbbVie Inc.
16.3.3. Roche Holding AG
16.3.4. Johnson & Johnson
16.3.5. Takeda Pharmaceutical Company Limited
16.3.6. Amgen Inc.
16.3.7. Novartis AG
16.3.8. AstraZeneca plc
16.3.9. Gilead Sciences, Inc.
16.3.10. Sanofi S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BLOOD CANCER DRUGS MARKET MULTI-CURRENCY
FIGURE 2. BLOOD CANCER DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. BLOOD CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BLOOD CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BLOOD CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BLOOD CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 59. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 61. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 62. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 63. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 69. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 70. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 71. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 108. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 110. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 111. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 112. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 116. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 118. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 119. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 120. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 132. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 134. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 135. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 136. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 140. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 142. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 143. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 144. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 172. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 174. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 175. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 176. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. QATAR BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 188. QATAR BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. QATAR BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 190. QATAR BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 191. QATAR BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 192. QATAR BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. QATAR BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. QATAR BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 196. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 197. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 198. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 199. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 200. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 220. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 221. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 222. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 223. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 224. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. TURKEY BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 228. TURKEY BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 229. TURKEY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 230. TURKEY BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 231. TURKEY BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 232. TURKEY BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. TURKEY BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. TURKEY BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 244. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 245. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 246. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 247. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 248. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. POLAND BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 252. POLAND BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 253. POLAND BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 254. POLAND BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 255. POLAND BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 256. POLAND BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. POLAND BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. POLAND BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 276. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 277. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 278. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 279. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 280. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 281. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 285. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 286. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 287. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 288. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 289. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 290. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 293. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 294. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 295. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 296. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 297. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 315. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 323. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 325. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 326. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 327. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 328. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 329. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 330. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 331. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 333. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 334. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 335. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 336. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2030 (USD MILLION)
TABLE 337. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 338. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 339. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 342. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 343. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 344. MALAYSIA BLOOD CANCER D

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Blood Cancer Drugs market report include:
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Roche Holding AG
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Novartis AG
  • AstraZeneca plc
  • Gilead Sciences, Inc.
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 50.96 Billion
Forecasted Market Value ( USD ) by 2030 $ 82.96 Billion
Compound Annual Growth Rate10.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Blood Cancer Drugs Market Report 2025 - Product Image

Blood Cancer Drugs Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Oncology Drugs Market by Drug Class, Route of Administration, Molecule Type, Indication, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Oncology Drugs Market by Drug Class, Route of Administration, Molecule Type, Indication, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Immunotherapy Drugs Market by Therapy Type, Indication, Route of Administration, End User, Mechanism of Action - Global Forecast to 2030 - Product Image

Immunotherapy Drugs Market by Therapy Type, Indication, Route of Administration, End User, Mechanism of Action - Global Forecast to 2030

  • Report
  • 193 Pages
  • Global
From
Hematological Cancer (Blood Cancer) Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Hematological Cancer (Blood Cancer) Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Chemotherapy Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Chemotherapy Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 100 Pages
  • Global
From

About the Blood Cancer Drug Market

The Blood Cancer Drug market is a subset of the Oncology Drugs market, which focuses on the treatment of cancer. Blood cancer drugs are used to treat a variety of blood cancers, including leukemia, lymphoma, and myeloma. These drugs are typically administered intravenously or orally, and may include chemotherapy, targeted therapy, and immunotherapy. Blood cancer drugs are designed to target cancer cells while minimizing damage to healthy cells, and may be used in combination with other treatments. The Blood Cancer Drug market is highly competitive, with a number of large pharmaceutical companies offering a range of treatments. Companies in the market include Novartis, Pfizer, Bristol-Myers Squibb, Celgene, and Merck. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.